

Table SI. Correlation analysis for OPRPN and SMR3A expression and clinicopathological features (n=96).

Clinicopathological features	OPRPN ^{high} SMR3a ^{high}	Others	P-value
Age, years			0.118
<58	8	34	
≥58	18	36	
Sex			0.62
Male	18	52	
Female	8	18	
TNM status			0.427
T1/T2	11	36	
T3/T4	15	34	
N0	5	9	0.432
N+	21	61	
Stage			0.577
I/II/III	7	23	
IV	19	47	
Grade			0.305
G1/G2	15	36	
G3	8	32	
missing	3	2	
Tobacco			0.079
Never/former	4	25	
Current	22	45	
Alcohol			0.601
Never/former	5	17	
Current	21	53	
HPV			0.17
HPV-	23	51	
HPV+	3	19	

SMR3A, submaxillary gland androgen-regulated protein 3A.

Table SII. Multivariate Cox regression analysis for DSS and PFS (n=96).

Factors	DSS		PFS	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years				
>58 vs. <58	1.000 (0.536-1.866)	0.999	1.107 (0.603-2.033)	0.743
Sex				
male vs. female	1.251 (0.579-2.701)	0.569	1.187 (0.569-2.475)	0.648
Stage				
IV vs. I/II/III				
pathological grade				
G3 vs. G1-2	1.158 (0.613-2.189)	0.651	1.245 (0.677-2.291)	0.480
Tobacco				
Current vs. Never/former	1.688 (0.822-3.467)	0.154	1.703 (0.831-3.488)	0.146
Alcohol				
Current vs. Never/former	1.131(0.530-2.416)	0.750	1.120 (0.533-2.350)	0.765
HPV status				
Driven vs. Non-driven	0.539 (0.200-1.457)	0.223	0.388 (0.145-1.038)	0.059
OPRPN low SMR3A high vs. others	9.586 (2.424-37.901)	0.001	9.270 (2.384-36.050)	0.001

DSS, disease-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; SMR3A, submaxillary gland androgen-regulated protein 3A.